New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
06:31 EDTIMGNImmunoGen announces preclinical findings for IMGN779
In preclinical findings reported at EHA, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro. IMGN779 can selectively kill leukemic cells (blasts) while sparing normal hematopoietic stem cells. IMGN779 was found to be highly active against human AML xenografts in vivo, demonstrating potent and targeted activity. IMGN779 was well tolerated without delayed toxicity in animal models. IMGN779 is on track to become the company’s next wholly owned clinical-stage compound. ImmunoGen is preparing to submit the IMGN779 IND in mid-2015.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IMGN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use